Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Sun Pharmaceutical Industries stock price, quote, forecast and news

SUNPHARMA.NS
INE044A01036

Price

1,865.75
Today +/-
+0.21
Today %
+1.06 %
P

Sun Pharmaceutical Industries stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Sun Pharmaceutical Industries stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Sun Pharmaceutical Industries stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Sun Pharmaceutical Industries stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Sun Pharmaceutical Industries's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Sun Pharmaceutical Industries Stock Price History

DateSun Pharmaceutical Industries Price
9/20/20241,865.75 undefined
9/19/20241,846.05 undefined
9/18/20241,836.00 undefined
9/17/20241,866.10 undefined
9/16/20241,862.95 undefined
9/13/20241,853.75 undefined
9/12/20241,858.60 undefined
9/11/20241,845.70 undefined
9/10/20241,836.35 undefined
9/9/20241,821.85 undefined
9/6/20241,824.55 undefined
9/5/20241,825.05 undefined
9/4/20241,832.85 undefined
9/3/20241,807.85 undefined
9/2/20241,816.30 undefined
8/30/20241,821.65 undefined
8/29/20241,799.20 undefined
8/28/20241,816.80 undefined
8/27/20241,789.40 undefined
8/26/20241,772.45 undefined

Sun Pharmaceutical Industries Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sun Pharmaceutical Industries, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sun Pharmaceutical Industries from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sun Pharmaceutical Industries’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sun Pharmaceutical Industries. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sun Pharmaceutical Industries’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sun Pharmaceutical Industries’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sun Pharmaceutical Industries’s growth potential.

Sun Pharmaceutical Industries Revenue, EBIT and net profit per share

DateSun Pharmaceutical Industries RevenueSun Pharmaceutical Industries EBITSun Pharmaceutical Industries Net Income
2027e634.52 B undefined152.52 B undefined140.5 B undefined
2026e596.9 B undefined140.01 B undefined130.11 B undefined
2025e537.87 B undefined119.17 B undefined112.53 B undefined
2024484.97 B undefined105.1 B undefined95.76 B undefined
2023438.86 B undefined92.81 B undefined84.74 B undefined
2022386.54 B undefined81.48 B undefined32.73 B undefined
2021334.98 B undefined64.54 B undefined29.04 B undefined
2020328.38 B undefined50.3 B undefined37.65 B undefined
2019290.66 B undefined49.03 B undefined26.65 B undefined
2018264.9 B undefined42.64 B undefined20.96 B undefined
2017315.78 B undefined86.27 B undefined69.64 B undefined
2016284.87 B undefined76.27 B undefined45.46 B undefined
2015273.92 B undefined69.35 B undefined45.39 B undefined
2014160.8 B undefined67.96 B undefined31.42 B undefined
2013113 B undefined46.39 B undefined29.83 B undefined
201280.2 B undefined29.86 B undefined26.57 B undefined
201157.28 B undefined17.6 B undefined18.16 B undefined
201040.08 B undefined12.17 B undefined13.51 B undefined
200942.72 B undefined17.41 B undefined18.18 B undefined
200833.57 B undefined14.55 B undefined14.87 B undefined
200721.37 B undefined5.91 B undefined7.84 B undefined
200616.38 B undefined4.3 B undefined5.73 B undefined
200511.87 B undefined3.78 B undefined3.96 B undefined

Sun Pharmaceutical Industries Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
1.92.83.584.786.147.519.739.8511.8716.3821.3733.5742.7240.0857.2880.2113160.8273.92284.87315.78264.9290.66328.38334.98386.55438.86484.97537.87596.9634.52
-47.2927.8333.5228.3222.2529.581.2520.5238.0230.4357.1027.28-6.2042.9340.0140.9142.3170.344.0010.85-16.129.7312.982.0115.3913.5310.5110.9110.976.30
46.1946.1644.6646.5349.4148.4553.3471.8369.3167.6169.2675.5475.4669.2870.1075.2977.5878.9971.6172.9369.3066.4068.2168.1170.4969.7172.7975.11---
0.881.291.62.233.033.645.197.078.2311.0814.825.3632.2427.7740.1560.3887.66127.03196.16207.74218.83175.9198.27223.66236.13269.47319.43364.27000
0.510.570.660.981.451.872.573.663.784.35.9114.5517.4112.1717.629.8646.3967.9669.3576.2786.2742.6449.0350.364.5481.4892.81105.1119.17140.01152.52
26.6420.3718.3920.5323.5524.8826.4437.2131.8226.2327.6843.3540.7630.3630.7337.2441.0642.2625.3226.7727.3216.1016.8715.3219.2721.0821.1521.6722.1623.4624.04
0.490.560.570.851.31.672.473.153.965.737.8414.8718.1813.5118.1626.5729.8331.4245.3945.4669.6420.9626.6537.6529.0432.7384.7495.76112.53130.11140.5
-14.261.9649.3052.3428.0648.0227.5825.9144.7136.8189.5922.26-25.6734.4246.2912.295.3144.500.1453.21-69.9127.1841.25-22.8712.70158.9113.0117.5115.627.99
-------------------------------
-------------------------------
5.335.481.851.841.871.871.871.861.912.072.022.072.072.072.072.072.072.072.412.412.42.42.42.42.42.42.42.4000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Sun Pharmaceutical Industries Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Sun Pharmaceutical Industries is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                       
0.030.060.090.340.410.260.820.9511.8115.3213.812.3916.665.0840.6148.9753.0295.72131.27138.79153.51139.77111.83113.6795.63127.17151.48191.14
0.250.40.070.060.130.160.210.210.240.390.420.50.9611.750.920.7924.122250.9367.6171.8178.1588.8494.2191.04105.14114.89113.03
0.510.571.61.351.231.532.593.233.735.458.6317.1812.755.7616.98.666.8910.0912.0712.9412.954.046.715.22.2116.7114.719.53
0.240.490.50.721.481.311.822.543.175.126.657.739.7610.7415.9922.5326.4632.5956.6764.2368.3368.8178.8678.7593.6292.39109.68102.95
0.10.0200000000.230.391.582.552.81.531.994.5526.4637.8515.8522.9425.5924.4524.7221.927.237.867.69
1.121.552.252.483.243.265.446.9218.9526.5229.8939.3742.6836.1275.93102.93115.03186.87288.78299.41329.54316.36310.69316.54304.42348.65398.62434.33
0.861.111.21.371.522.113.14.525.898.539.7210.2914.4316.7824.6929.5837.2343.485.3287.87100.6105.94109.38112.26111.72111.69113.54113
000000000000000011.067.8814.4620.5815.5330.6139.6452.4664.8352.1554.5764.41
000000000000003.791.175.914.813.0716.831.9559.7237.3739.3938.2226.2224.4924.86
000.450.460.470.470.390.410.330.450.40.761.7702.883.163.794.0711.5336.2648.851.1863.5463.656.6161.9293.2786.66
00000001.611.540.510.71.733.254.067.7210.2221.0829.1254.8556.3555.3656.0759.5664.8262.8865.9187.1385.99
0.190.50.630.50.650.590.041.86.513.633.28.6520.533.768.7217.6811.7317.5833.638.0332.3225.3126.7633.473831.5435.8245.38
1.051.612.282.332.633.163.538.3514.2613.1114.0221.4239.9554.647.861.8190.8106.84212.82255.89284.57328.8336.25365.98372.25349.43408.82420.3
2.173.164.534.815.876.428.9715.2733.2139.6343.9160.7982.6490.72123.73164.74205.83293.71501.6555.3614.1645.16646.94682.53676.67698.08807.44854.63
                                                       
0.150.150.660.650.80.470.620.620.940.940.981.041.041.041.041.041.042.072.072.412.42.42.42.42.42.42.42.4
0000000000.165.1715.115.115.115.115.115.114.2218.3718.5911.911.9311.9311.8711.8711.8711.8711.87
1.572.072.5133.864.965.047.4310.4314.8221.633.9248.8859.0776.197.66121.44149.06252.72288.8344.71357.17372.86392.79405.62416.1475.74541.19
0000.01000.10.12-0.06-0.02-0.01-0.145.443.092.68.5612.3319.90.3415.947.0610.0925.2745.3740.4548.1267.7970.96
0000000000000000006.924.080.341.561.620.224.291.622.1510.24
1.722.223.163.654.655.425.768.1611.3115.927.7349.9270.4578.2994.83122.36149.9185.25280.41329.83366.4383.14414.09452.64464.63480.11559.95636.67
0.090.10.150.30.320.380.630.931.061.111.52.392.543.196.459.9210.5813.2832.4335.8343.9547.6641.4840.9439.7444.956.8256.53
0000000.040.020.020.030.020.0200.170.040.040.030.020.320.440.380.340.380.097.3814.8315.1316.89
0.170.430.30.320.540.590.961.181.52.371.523.964.664.228.1314.5716.3621.4744.4241.3150.5864.5141.6253.1784.63104.2763.8666.72
000.240.0600000000002.081.110.8324.462.1352.0666.5579.883.7155.4924.454.6959.5828.44
000000000000000.610.560.620.72141.817.416.346.217.375.263.43.681.26
0.260.530.70.680.860.971.622.122.593.513.056.377.27.5817.3126.1928.4159.9153.29131.44178.87198.64173.4157.07161.46172.08199.06169.84
0.190.410.670.490.3601.264.1318.2318.7511.141.441.791.711.571.551.150.4913.631.114.3617.7215.2320.298.984.825.63.04
0000000.290.780.921.141.561.181.231.211.351.552.052.760.751.193.292.191.040.580.450.320.321.55
000000000000000.21.487.9626.1125.0320.8913.284.6310.0513.3410.9910.29.39.14
0.190.410.670.490.3601.554.9119.1519.8912.72.613.022.923.124.5811.1729.3539.3853.1930.9324.5426.3234.2120.4115.3315.2213.73
0.450.931.371.171.210.973.187.0321.7423.415.758.9910.2210.520.4330.7739.5889.25192.67184.63209.8223.18199.71191.28181.87187.42214.28183.57
2.173.164.534.815.876.398.9415.1933.0539.343.4758.980.6788.79115.26153.13189.48274.5473.09514.45576.19606.32613.8643.92646.5667.53774.24820.24
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Sun Pharmaceutical Industries provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Sun Pharmaceutical Industries's financial health and stability.

Assets

Sun Pharmaceutical Industries's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Sun Pharmaceutical Industries must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Sun Pharmaceutical Industries after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Sun Pharmaceutical Industries's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.510.570.610.971.451.872.663.814.215.978.3415.9919.4914.1520.3633.5543.1545.8164.0365.7190.4834.7938.150.127.9944.8194.08
0.060.080.10.170.160.180.210.290.410.610.810.971.231.532.052.913.364.0911.9510.3812.651517.5320.5320.821.4425.29
000000000000000000000000000
-0.02-0.33-0.23-0.41-0.91-0.56-2.26-1.54-0.94-3.34-4.6-11.16-1.66-6.14.18-12.32-9.58-5.82-3.09-17.42-24.66-8.34-35.37-4.4715.6125.7-66.05
0.050.10.01-00-0.02-0.010.12-0.1-1.37-2.16-0.752.59-1.77-3.76-1.8-1.76-4.49-4.218.19-7.64-1.182.15-0.6-2.7-1.691.93
0.050.110.120.10.080.040.030.070.080.160.130.090.080.060.870.290.380.233.53.013.344.774.612.721.440.730.99
0.020.010.030.050.10.190.170.140.110.170.441.821.691.750.692.2710.747.8917.419.8920.577.428.8613.4610.03-9.6915.1
0.590.420.490.740.71.470.612.683.581.872.45.0521.657.8122.8322.3535.1739.5968.6866.8670.8240.2722.4265.5561.790.2655.26
-377-358-652-373-326-709-676-2,884-1,616-3,406-2,365-2,024-6,101-2,841-4,219-7,129-8,786-9,060-23,498-34,035-36,929-19,608-32,128-15,420-11,701-14,950-20,855
-0.47-0.61-0.78-0.29-0.28-0.84-0.77-4.32-6.351.790.64-6.06-17.73-2.14-18.48-8.63-26.35-23.67-28.66-43.72-42.22-33.71-6.81-25.895.36-57.25-79.44
-0.09-0.25-0.130.090.05-0.13-0.1-1.44-4.745.23-4.04-11.630.7-14.26-1.5-17.57-14.61-5.16-9.68-5.29-14.125.32-10.4717.06-42.3-58.58
000000000000000000000000000
-0.080.27-0.08-0.18-0.070.011.172.4114.490.8-1.71-0.030.35-0.08-3.79-1.05-0.7522.75-5.48-6.7810.725.88-2.37-31.23-44.9-27.6549.95
04504-10-170-327-179-83-14100-1400000074991-9940-55900
-0.120.220.31-0.49-0.36-0.590.731.7713.64-0.15-4.50.66-2.67-3.46-8.04-5.44-6.655.07-11.87-18.89-22.85-15.39-27.31-57.15-59.8-51.9323.76
100000-29-123-156-253-483717-949-543-1,408-872-1,500-12,508-4,030-4,953-31,136-13,144-20,135-12,130686-2,691-1,000
-37-57-121-298-119-273-233-435-552-695-2,303-16-2,070-2,844-2,847-3,524-4,401-5,175-3,105-7,243-2,430-8,134-4,802-13,792-15,594-21,589-25,188
0.010.030.02-0.040.060.040.560.1310.863.52-1.46-0.351.252.21-3.719.423.1622.929.278.486.11-7.36-8.44-13.865.96-17.651.15
21459-158364374761-71-2061,959-1,534303,02615,5484,97018,61215,21626,38730,53245,17732,82433,89320,661-9,70850,12850,002.475,309.534,404.4
000000000000000000000000000

Sun Pharmaceutical Industries stock margins

The Sun Pharmaceutical Industries margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sun Pharmaceutical Industries. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sun Pharmaceutical Industries.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sun Pharmaceutical Industries's sales revenue. A higher gross margin percentage indicates that the Sun Pharmaceutical Industries retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sun Pharmaceutical Industries's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sun Pharmaceutical Industries's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sun Pharmaceutical Industries's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sun Pharmaceutical Industries. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sun Pharmaceutical Industries's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sun Pharmaceutical Industries Margin History

Sun Pharmaceutical Industries Gross marginSun Pharmaceutical Industries Profit marginSun Pharmaceutical Industries EBIT marginSun Pharmaceutical Industries Profit margin
2027e75.11 %24.04 %22.14 %
2026e75.11 %23.46 %21.8 %
2025e75.11 %22.16 %20.92 %
202475.11 %21.67 %19.75 %
202372.79 %21.15 %19.31 %
202269.71 %21.08 %8.47 %
202170.49 %19.27 %8.67 %
202068.11 %15.32 %11.47 %
201968.21 %16.87 %9.17 %
201866.4 %16.1 %7.91 %
201769.3 %27.32 %22.05 %
201672.93 %26.77 %15.96 %
201571.61 %25.32 %16.57 %
201478.99 %42.26 %19.54 %
201377.58 %41.06 %26.4 %
201275.29 %37.24 %33.13 %
201170.1 %30.73 %31.71 %
201069.28 %30.36 %33.71 %
200975.46 %40.76 %42.55 %
200875.54 %43.35 %44.3 %
200769.26 %27.68 %36.7 %
200667.61 %26.23 %34.99 %
200569.31 %31.82 %33.38 %

Sun Pharmaceutical Industries Stock Sales Revenue, EBIT, Earnings per Share

The Sun Pharmaceutical Industries earnings per share therefore indicates how much revenue Sun Pharmaceutical Industries has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sun Pharmaceutical Industries earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sun Pharmaceutical Industries's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sun Pharmaceutical Industries’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sun Pharmaceutical Industries's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sun Pharmaceutical Industries Revenue, EBIT and net profit per share

DateSun Pharmaceutical Industries Sales per ShareSun Pharmaceutical Industries EBIT per shareSun Pharmaceutical Industries Earnings per Share
2027e264.46 undefined0 undefined58.56 undefined
2026e248.78 undefined0 undefined54.23 undefined
2025e224.18 undefined0 undefined46.9 undefined
2024202.13 undefined43.8 undefined39.91 undefined
2023182.91 undefined38.68 undefined35.32 undefined
2022161.11 undefined33.96 undefined13.64 undefined
2021139.61 undefined26.9 undefined12.1 undefined
2020136.88 undefined20.97 undefined15.69 undefined
2019121.16 undefined20.44 undefined11.11 undefined
2018110.42 undefined17.77 undefined8.74 undefined
2017131.36 undefined35.89 undefined28.97 undefined
2016118.35 undefined31.69 undefined18.89 undefined
2015113.85 undefined28.82 undefined18.87 undefined
201477.65 undefined32.81 undefined15.17 undefined
201354.56 undefined22.4 undefined14.4 undefined
201238.72 undefined14.42 undefined12.83 undefined
201127.66 undefined8.5 undefined8.77 undefined
201019.35 undefined5.87 undefined6.52 undefined
200920.63 undefined8.41 undefined8.78 undefined
200816.21 undefined7.03 undefined7.18 undefined
200710.6 undefined2.93 undefined3.89 undefined
20067.92 undefined2.08 undefined2.77 undefined
20056.21 undefined1.97 undefined2.07 undefined

Sun Pharmaceutical Industries business model

Sun Pharmaceutical Industries Ltd is a leading company in the pharmaceutical industry, with its headquarters in Mumbai. The company was founded in 1983 by Dilip Shanghvi, a pharmacist who started with a capital of only 2000 rupees. The company's history began with the manufacturing of psychotropic drugs. However, Sun Pharma quickly expanded into other areas, including dermatology, cardiology, pain medicine, and oncology. Over the years, the company has acquired many companies and established itself in the pharmaceutical industry through mergers and acquisitions. It has a market presence in the USA, Europe, Japan, Australia, and Africa. Sun Pharmaceutical Industries Ltd's business model is based on the development and manufacturing of pharmaceuticals, generics, and biosimilars, as well as the provision of healthcare services. The company aims to provide innovative and affordable medicines to patients worldwide. Sun Pharma is divided into various segments, including generic drug manufacturing, specialty pharmaceuticals, and its own developed oncology platform. In the generic drug manufacturing, Sun Pharma is considered one of the world's largest suppliers, covering a wide range of therapeutic areas. One of its most well-known segments is the manufacturing of nerve blockers and painkillers. In fact, Sun Pharma was the first Indian corporation to receive approval for an opioid painkiller in the United States. Sun Pharmaceutical Industries Ltd offers a wide range of products, including: 1. Generics: The company is known for its cost-effective and high-quality generics, providing affordable treatment for a variety of diseases. 2. Biosimilars: Sun Pharma is also involved in the manufacturing of biosimilars, which has proven to be an important area. 3. Specialty pharmaceuticals: This segment includes a wide range of specialty pharmaceuticals, including medications for diabetes, asthma, and HIV treatment. 4. Oncology platform: Sun Pharma is focused on developing and marketing a wide range of oncology products, including cytostatics, immunotherapeutics, and cancer treatments. Sun Pharmaceutical Industries Ltd has a wide network of research and development facilities in India and around the world. The company has acquired numerous patents and licenses to develop and market innovative drugs. A particular capability lies in developing complex technologies and techniques to offer cost-effective therapies. In the past, Sun Pharma has faced some controversies, particularly related to the trading of opioids in the USA. However, the company has overcome these challenges and continues to focus on providing affordable and innovative medicines. In summary, Sun Pharmaceutical Industries Ltd is a leading company in the pharmaceutical industry. With a wide range of products and services and a global presence, it is a significant player in the global market. The company remains dedicated to developing innovative and affordable drugs to meet the needs of patients worldwide. Sun Pharmaceutical Industries is one of the most popular companies on Eulerpool.com.

Sun Pharmaceutical Industries SWOT Analysis

Strengths

1. Strong product portfolio: Sun Pharmaceutical Industries Ltd has a diverse range of medications and healthcare products, catering to various therapeutic segments. This enables the company to effectively serve a wide customer base and maintain a competitive edge in the market.

2. Established brand reputation: Sun Pharma, as it is commonly known, has been in the pharmaceutical industry for several decades and has earned a strong reputation for its quality medications and successful track record. This brand recognition gives the company an advantage when entering new markets or launching new products.

3. Robust manufacturing capabilities: The company owns several state-of-the-art manufacturing facilities that adhere to stringent quality standards. This enables Sun Pharma to produce high-quality medications in large volumes, meeting the growing demand both domestically and internationally.

Weaknesses

1. Dependence on a few key markets: Although Sun Pharma has a global presence, the company heavily relies on a limited number of markets for the majority of its revenue. Any adverse changes in these markets, such as unfavorable regulations or economic downturns, can significantly impact Sun Pharma's business and financial performance.

2. Product recalls and regulatory issues: In the past, Sun Pharma has faced some product recalls and regulatory compliance issues, which resulted in reputational damage and financial losses. These incidents highlight a weakness in the company's quality control and regulatory processes that need to be addressed and improved.

Opportunities

1. Growing global pharmaceutical market: The global pharmaceutical market is expanding rapidly due to the increasing prevalence of diseases and the aging population. Sun Pharma can capitalize on this opportunity by expanding its product line, entering new markets, and forming strategic alliances to enhance its market share and profitability.

2. Investments in research and development: By investing in research and development (R&D), Sun Pharma can develop innovative medications and formulations, ensuring a competitive advantage in the market. The company can also focus on developing generic versions of popular drugs or other niche therapeutic areas to tap into untapped markets.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, with numerous global and local players vying for market share. Sun Pharma faces competition from both established pharmaceutical companies and emerging generics manufacturers. This increased competition can affect pricing and profitability.

2. Stringent regulations and pricing pressures: Governments around the world are imposing stricter regulations on pharmaceutical companies, focusing on safety, efficacy, and pricing. Compliance with these regulations can be challenging and costly for Sun Pharma, potentially leading to decreased profit margins. Additionally, pricing pressures can negatively impact the company's revenue and profitability.

Sun Pharmaceutical Industries Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Sun Pharmaceutical Industries historical P/E ratio, EBIT, and P/S ratio.

Sun Pharmaceutical Industries shares outstanding

The number of shares was Sun Pharmaceutical Industries in 2023 — This indicates how many shares 2.399 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sun Pharmaceutical Industries earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sun Pharmaceutical Industries's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sun Pharmaceutical Industries’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sun Pharmaceutical Industries's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sun Pharmaceutical Industries Stock splits

In Sun Pharmaceutical Industries's history, there have been no stock splits.

Sun Pharmaceutical Industries dividend history and estimates

In 2023, Sun Pharmaceutical Industries paid a dividend amounting to 11.5 INR. Dividend means that Sun Pharmaceutical Industries distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Sun Pharmaceutical Industries provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Sun Pharmaceutical Industries’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Sun Pharmaceutical Industries's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Sun Pharmaceutical Industries Dividend History

DateSun Pharmaceutical Industries Dividend
2027e13.85 undefined
2026e13.87 undefined
2025e13.84 undefined
202413.5 undefined
202311.5 undefined
202210 undefined
20217.5 undefined
20204 undefined
20192.75 undefined
20182 undefined
20173.5 undefined
20161 undefined
20153 undefined
20141.5 undefined
20132.5 undefined
20122.13 undefined
20111.75 undefined
20101.38 undefined
20091.38 undefined
20081.05 undefined
20070.68 undefined
20060.55 undefined
20050.38 undefined

Sun Pharmaceutical Industries dividend payout ratio

In 2023, Sun Pharmaceutical Industries had a payout ratio of 53.59%. The payout ratio indicates the percentage of the company's profits that Sun Pharmaceutical Industries distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Sun Pharmaceutical Industries represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Sun Pharmaceutical Industries could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Sun Pharmaceutical Industries's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Sun Pharmaceutical Industries Payout Ratio History

DateSun Pharmaceutical Industries Payout ratio
2027e62.06 %
2026e59.95 %
2025e63.29 %
202462.96 %
202353.59 %
202273.31 %
202161.97 %
202025.49 %
201924.75 %
201822.91 %
201712.08 %
20165.3 %
201515.9 %
20149.88 %
201317.36 %
201216.56 %
201119.93 %
201021.09 %
200915.66 %
200814.62 %
200717.35 %
200619.86 %
200518.12 %
Unfortunately, there are currently no price targets and forecasts available for Sun Pharmaceutical Industries.

Sun Pharmaceutical Industries latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202410.22 11.8  (15.42 %)2025 Q1
3/31/20249.27 11.53  (24.36 %)2024 Q4
12/31/20239.96 10.79  (8.35 %)2024 Q3
9/30/20238.94 9.9  (10.8 %)2024 Q2
6/30/20238.55 9.11  (6.53 %)2024 Q1
3/31/20237.78 9.01  (15.75 %)2023 Q4
12/31/20228.84 9  (1.81 %)2023 Q3
9/30/20228.34 9.4  (12.72 %)2023 Q2
6/30/20227.78 8.6  (10.55 %)2023 Q1
3/31/20227.02 6.92  (-1.49 %)2022 Q4
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Sun Pharmaceutical Industries stock

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

64

👫 Social

72

🏛️ Governance

45

Environment

Scope 1 - Direct Emissions
67,203
Scope 2 - Indirect emissions from purchased energy
352,678
Scope 3 - Indirect emissions within the value chain
357,266
Total CO₂ emissions
419,881
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees14.94
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic❌

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies✅
Antitrust law✅

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sun Pharmaceutical Industries list of shareholders

%
Name
Stocks
Change
Date
9.59812 % Shanghvi (Dilip Shantilal)230,285,690012/31/2023
40.30591 % Shanghvi Finance Pvt. Ltd.967,051,732012/31/2023
3.56272 % SBI Funds Management Pvt. Ltd.85,479,6001,304,23212/31/2023
3.19836 % ICICI Prudential Asset Management Co. Ltd.76,737,511-538,2123/31/2024
2.83863 % Life Insurance Corporation of India68,106,696-1,692,00012/31/2023
1.67358 % Aditya Medisales, Ltd.40,153,960012/31/2023
1.45572 % The Vanguard Group, Inc.34,926,682-178,4763/31/2024
1.20163 % Valia (Raksha Sudhir)28,830,352012/31/2023
1.14703 % GIC Private Limited27,520,426-1,168,65512/31/2023
1.08981 % BlackRock Institutional Trust Company, N.A.26,147,548768,8573/31/2024
1
2
3
4
5
...
10

Sun Pharmaceutical Industries Executives and Management Board

Mr. Dilip Shanghvi67
Sun Pharmaceutical Industries Managing Director, Executive Director (since 2012)
Compensation 54.53 M
Mr. C. S. Muralidharan
Sun Pharmaceutical Industries Chief Financial Officer
Compensation 38.89 M
Mr. Sailesh Desai68
Sun Pharmaceutical Industries Whole-Time Director (since 1999)
Compensation 19.73 M
Mr. Uday Baldota53
Sun Pharmaceutical Industries Chief Executive Officer - Taro Pharmaceutical Industries Limited
Compensation 14.96 M
Dr. Pawan Goenka68
Sun Pharmaceutical Industries Lead Non-Executive Independent Director
Compensation 8.5 M
1
2
3
4
...
5

Most common questions regarding Sun Pharmaceutical Industries

What values and corporate philosophy does Sun Pharmaceutical Industries represent?

Sun Pharmaceutical Industries Ltd represents core values of integrity, innovation, and excellence. As a leading pharmaceutical company, Sun Pharma is dedicated to providing high-quality, affordable healthcare solutions worldwide. The company prides itself on its robust corporate philosophy, focusing on ethical business practices, patient-centricity, and continuous improvement. Sun Pharma strives to enhance access to life-saving medications and transform patients' lives through cutting-edge research and development. With a commitment to social responsibility and sustainability, Sun Pharma aims to make a positive impact on communities and create long-term value for its stakeholders.

In which countries and regions is Sun Pharmaceutical Industries primarily present?

Sun Pharmaceutical Industries Ltd is primarily present in several countries and regions around the world. The company has a strong presence in India, where it is headquartered, and it has also expanded its operations globally. Sun Pharma has a significant presence in the United States, making it one of the leading generic pharmaceutical companies in the country. Additionally, the company has a strong market presence in emerging markets such as Russia, Brazil, South Africa, and several countries in Europe. With its global footprint, Sun Pharmaceutical Industries Ltd continues to establish itself as a prominent player in the international pharmaceutical industry.

What significant milestones has the company Sun Pharmaceutical Industries achieved?

Sun Pharmaceutical Industries Ltd has achieved several significant milestones throughout its history. Notably, the company became the largest pharmaceutical company in India and one of the top generic companies globally. Sun Pharma successfully acquired Taro Pharmaceutical Industries, a US-based company, which significantly expanded its presence in the international market. Moreover, the acquisition of Ranbaxy Laboratories positioned Sun Pharma as the largest pharmaceutical company in India and the fifth-largest globally. Sun Pharma has also received numerous accolades and awards for its research and development efforts, innovation, and manufacturing excellence. These milestones highlight Sun Pharmaceutical Industries Ltd's continuous growth and success in the pharmaceutical industry.

What is the history and background of the company Sun Pharmaceutical Industries?

Sun Pharmaceutical Industries Ltd, founded in 1983, is a renowned Indian multinational pharmaceutical company. With its headquarters in Mumbai, the company has consistently grown and developed a strong presence in the global pharmaceutical market. Sun Pharma has a rich history of delivering high-quality and affordable medications across a wide range of therapeutic areas. Their focus on research and development, combined with strategic collaborations and acquisitions, has propelled them to become a leading player in the industry. Sun Pharmaceutical Industries Ltd has significantly contributed to improving global healthcare and continues to be a trusted name in the pharmaceutical sector.

Who are the main competitors of Sun Pharmaceutical Industries in the market?

The main competitors of Sun Pharmaceutical Industries Ltd in the market include Cipla Ltd, Lupin Ltd, Dr. Reddy's Laboratories Ltd, and Aurobindo Pharma Ltd.

In which industries is Sun Pharmaceutical Industries primarily active?

Sun Pharmaceutical Industries Ltd is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Sun Pharmaceutical Industries?

The business model of Sun Pharmaceutical Industries Ltd is focused on manufacturing and distributing pharmaceutical products across the globe. As one of the largest pharmaceutical companies in India, Sun Pharma operates through various divisions including formulations, active pharmaceutical ingredients (APIs), and research and development. With a strong emphasis on product quality and innovation, Sun Pharma aims to improve healthcare accessibility by providing high-quality and affordable medications to patients worldwide. The company’s wide portfolio encompasses a diverse range of therapeutic areas such as cardiology, psychiatry, neurology, and more. Sun Pharmaceutical Industries Ltd strives to constantly evolve and grow, serving the healthcare industry with integrity and excellence.

What is the P/E ratio of Sun Pharmaceutical Industries 2024?

The Sun Pharmaceutical Industries P/E ratio is 46.75.

What is the P/S ratio of Sun Pharmaceutical Industries 2024?

The Sun Pharmaceutical Industries P/S ratio is 9.23.

What is the AlleAktien quality score of Sun Pharmaceutical Industries?

The AlleAktien quality score for Sun Pharmaceutical Industries is 8/10.

What is the revenue of Sun Pharmaceutical Industries 2024?

The Sun Pharmaceutical Industries revenue is 484.97 B INR.

How high is the profit of Sun Pharmaceutical Industries 2024?

The Sun Pharmaceutical Industries profit is 95.76 B INR.

What is the business model of Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd is an Indian multinational company that specializes in the development, manufacturing, and marketing of generic drugs and innovative products. The company operates in over 150 countries and has a portfolio of over 2000 products. The business model of Sun Pharma is divided into several divisions. Firstly, there is the generic drugs division, which specializes in the manufacturing and marketing of affordable medications. The company produces generics in various therapeutic areas such as neurology, oncology, cardiology, gastroenterology, and many others, providing effective and affordable treatment options for patients. In addition to the generic drugs division, Sun Pharma also has a comprehensive branded products division. Here, the company focuses on developing innovative therapies and marketing branded products in key areas such as dermatology, orthopedics, ophthalmology, and psychiatry. This allows Sun Pharma to leverage its competitive advantage and differentiate itself from other companies. In the research and development field, Sun Pharma collaborates closely with international partners. The company is committed to expanding its portfolio of innovative products and focuses on areas such as oncology, neurology, and dermatological therapies. An example of Sun Pharma's commitment to research and development is the introduction of Tildrakizumab, a groundbreaking product for the treatment of moderate to severe plaque psoriasis. This product was developed in partnership with Almirall SA and successfully launched in the United States and Europe. Another example of Sun Pharma's leading position in the market is products like Ilumya, a medication for the treatment of psoriasis, and Ezallor, a medication for lowering cholesterol levels. These products have been successfully introduced in the United States and have the potential to significantly increase the company's revenue in the future. Sun Pharma values quality and strictly adheres to international guidelines and standards. The company is certified by various certification bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In addition to the above-mentioned business divisions, Sun Pharma also operates a strategic investment portfolio to ensure long-term growth and stability. The company invests in promising companies that align with its business areas, demonstrating a high level of strategic foresight. Overall, the business model of Sun Pharmaceutical Industries Ltd is focused on growth. Through a variety of strategic business units and products, the company can fully leverage its global potential and expand its portfolio. The pursuit of quality and innovation is an integral part of the company's philosophy and is at the center of each business unit.

What is the Sun Pharmaceutical Industries dividend?

Sun Pharmaceutical Industries pays a dividend of 10 INR distributed over payouts per year.

How often does Sun Pharmaceutical Industries pay dividends?

The dividend cannot currently be calculated for Sun Pharmaceutical Industries or the company does not pay out a dividend.

What is the Sun Pharmaceutical Industries ISIN?

The ISIN of Sun Pharmaceutical Industries is INE044A01036.

What is the Sun Pharmaceutical Industries ticker?

The ticker of Sun Pharmaceutical Industries is SUNPHARMA.NS.

How much dividend does Sun Pharmaceutical Industries pay?

Over the past 12 months, Sun Pharmaceutical Industries paid a dividend of 13.5 INR . This corresponds to a dividend yield of about 0.72 %. For the coming 12 months, Sun Pharmaceutical Industries is expected to pay a dividend of 13.84 INR.

What is the dividend yield of Sun Pharmaceutical Industries?

The current dividend yield of Sun Pharmaceutical Industries is 0.72 %.

When does Sun Pharmaceutical Industries pay dividends?

Sun Pharmaceutical Industries pays a quarterly dividend. This is distributed in the months of March, August, March, August.

How secure is the dividend of Sun Pharmaceutical Industries?

Sun Pharmaceutical Industries paid dividends every year for the past 23 years.

What is the dividend of Sun Pharmaceutical Industries?

For the upcoming 12 months, dividends amounting to 13.84 INR are expected. This corresponds to a dividend yield of 0.74 %.

In which sector is Sun Pharmaceutical Industries located?

Sun Pharmaceutical Industries is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sun Pharmaceutical Industries kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sun Pharmaceutical Industries from 8/16/2024 amounting to 5 INR, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Sun Pharmaceutical Industries pay the last dividend?

The last dividend was paid out on 8/16/2024.

What was the dividend of Sun Pharmaceutical Industries in the year 2023?

In the year 2023, Sun Pharmaceutical Industries distributed 11.5 INR as dividends.

In which currency does Sun Pharmaceutical Industries pay out the dividend?

The dividends of Sun Pharmaceutical Industries are distributed in INR.

All fundamentals about Sun Pharmaceutical Industries

Our stock analysis for Sun Pharmaceutical Industries Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sun Pharmaceutical Industries Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.